{"transactions":[{"id":912705,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28283,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28283},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912704,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15476,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The restricted stock units (\"RSUs\") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15476},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912703,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F8","text":"The stock option was granted to the Reporting Person in 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":12.69,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912702,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":12.48,"underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912701,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":11.12,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912700,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":12.74,"underlying":"Common Stock","underlying_shares":90500},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912699,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.9,"underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912698,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock - Performance Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912697,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock - Performance Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":42424,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027."}],"balance_after":42424,"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912696,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock - Performance Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46430,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912695,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock - Performance Stock Units","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":46430,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents performance-based restricted stock units (\"PSUs\") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies (\"rTSR\") over a performance period ending on December 31, 2026."}],"balance_after":46430,"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":912694,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2026-02-10T16:15:24.000Z","date":"2026-02-10","kind":"other","planned":false,"acquired":false,"shares":60204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001781117-26-000002","document":"form4-02102026_040217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000178111726000002/form4-02102026_040217.xml","form_type":"4"}},{"id":958747,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":false,"shares":14141,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2025 (the \"Effective Date\"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger\nSub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units (\"PSUs\") and restricted stock units (\"RSUs\") previously granted to the\nReporting Person, effective as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025."}],"balance_after":28282,"derivative":{"underlying":"Common Stock","underlying_shares":14141},"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":958746,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":false,"shares":15477,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2025 (the \"Effective Date\"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger\nSub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units (\"PSUs\") and restricted stock units (\"RSUs\") previously granted to the\nReporting Person, effective as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024."}],"balance_after":15477,"derivative":{"underlying":"Common Stock","underlying_shares":15477},"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":958745,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":36141,"price":15.38,"value":555848.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of PSUs and RSUs."}],"balance_after":60204,"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":958744,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":true,"shares":14141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2025 (the \"Effective Date\"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger\nSub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units (\"PSUs\") and restricted stock units (\"RSUs\") previously granted to the\nReporting Person, effective as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":96345,"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":958743,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":true,"shares":15477,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2025 (the \"Effective Date\"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger\nSub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units (\"PSUs\") and restricted stock units (\"RSUs\") previously granted to the\nReporting Person, effective as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":82204,"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":958742,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-29T16:15:14.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2025 (the \"Effective Date\"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger\nSub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units (\"PSUs\") and restricted stock units (\"RSUs\") previously granted to the\nReporting Person, effective as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents PSUs previously granted to the Reporting Person that vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies (\"rTSR\") over a performance period ending on December 31, 2025. Each\nPSU represents a contingent right to receive one share of common stock. On the Effective Date, the Board of Directors of the Issuer determined that these PSUs (which represent 125% of the target number of PSUs) were earned according to achievement of the rTSR\nperformance condition over a shortened performance period, with the Issuer's total stockholder return determined based on the amount payable for a share of the Issuer's common stock pursuant to the Merger Agreement ($15.50), and approved such acceleration of vesting\nof the earned PSUs."}],"balance_after":66727,"source":{"system":"sec-edgar","filing":"0001628280-25-058992","document":"wk-form4_1767042911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000162828025058992/wk-form4_1767042911.xml","form_type":"4"}},{"id":1256688,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-20T19:29:45.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":15477,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."}],"balance_after":30953,"derivative":{"underlying":"Common Stock","underlying_shares":15477},"source":{"system":"sec-edgar","filing":"0001029142-25-000055","document":"wk-form4_1740097777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000055/wk-form4_1740097777.xml","form_type":"4"}},{"id":1256687,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-20T19:29:45.000Z","date":"2025-02-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":4975,"price":12.93,"value":64326.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units."}],"balance_after":29227,"source":{"system":"sec-edgar","filing":"0001029142-25-000055","document":"wk-form4_1740097777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000055/wk-form4_1740097777.xml","form_type":"4"}},{"id":1256686,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-20T19:29:45.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":15477,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."}],"balance_after":34202,"source":{"system":"sec-edgar","filing":"0001029142-25-000055","document":"wk-form4_1740097777.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000055/wk-form4_1740097777.xml","form_type":"4"}},{"id":1264668,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":42424,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025."}],"balance_after":42424,"derivative":{"underlying":"Common Stock","underlying_shares":42424},"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1264667,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the\nshares subject to the option vesting each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter."}],"balance_after":70000,"derivative":{"exercise_price":12.69,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1264666,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"exercise","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1264665,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."}],"balance_after":16000,"derivative":{"underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1264664,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":5318,"price":12.69,"value":67485.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units."}],"balance_after":18725,"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1264663,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-18T17:10:14.000Z","date":"2025-02-13","kind":"exercise","planned":false,"acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition."}],"balance_after":24043,"source":{"system":"sec-edgar","filing":"0001029142-25-000035","document":"wk-form4_1739916608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000035/wk-form4_1739916608.xml","form_type":"4"}},{"id":1272301,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T16:59:52.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":5333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0001029142-25-000022","document":"wk-form4_1739397585.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000022/wk-form4_1739397585.xml","form_type":"4"}},{"id":1272300,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-12T16:59:52.000Z","date":"2025-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1997,"price":13.2,"value":26360.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units."}],"balance_after":8043,"source":{"system":"sec-edgar","filing":"0001029142-25-000022","document":"wk-form4_1739397585.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000022/wk-form4_1739397585.xml","form_type":"4"}},{"id":1272299,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-02-12T16:59:52.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":true,"shares":5333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":10040,"source":{"system":"sec-edgar","filing":"0001029142-25-000022","document":"wk-form4_1739397585.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000022/wk-form4_1739397585.xml","form_type":"4"}},{"id":1635059,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2024-02-20T16:44:37.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":46430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Code A: Grant, award or other acquisition"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual\nanniversary of February 15, 2024."}],"balance_after":46430,"derivative":{"underlying":"Common Stock","underlying_shares":46430},"source":{"system":"sec-edgar","filing":"0001209191-24-003548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919124003548/doc4.xml","form_type":"4"}},{"id":1635058,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-02-20T16:44:37.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Code A: Grant, award or other acquisition"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of\nFebruary 15, 2024, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter."}],"balance_after":65000,"derivative":{"exercise_price":12.48,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-24-003548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919124003548/doc4.xml","form_type":"4"}},{"id":1646973,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2024-02-13T17:16:46.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":false,"shares":5333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"kind","element":"transactionCoding","label":"F1","text":"Code M: Exercise or conversion of derivative security"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":5333,"derivative":{"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0001209191-24-003196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919124003196/doc4.xml","form_type":"4"}},{"id":1646972,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2024-02-13T17:16:46.000Z","date":"2024-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2985,"price":12.82,"value":38267.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Code F: Payment of exercise price or tax liability by delivering or withholding securities"},{"field":"shares","element":"transactionShares","label":"F4","text":"Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units."}],"balance_after":4707,"source":{"system":"sec-edgar","filing":"0001209191-24-003196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919124003196/doc4.xml","form_type":"4"}},{"id":1646971,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2024-02-13T17:16:46.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":true,"shares":5333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Code M: Exercise or conversion of derivative security"},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":7692,"source":{"system":"sec-edgar","filing":"0001209191-24-003196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919124003196/doc4.xml","form_type":"4"}},{"id":1984497,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2023-03-01T16:52:25.000Z","date":"2023-02-27","kind":"exercise","acquired":false,"shares":5334,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":10666,"derivative":{"underlying":"Common Stock","underlying_shares":5334},"source":{"system":"sec-edgar","filing":"0001209191-23-014170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123014170/doc4.xml","form_type":"4"}},{"id":1984496,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2023-03-01T16:52:25.000Z","date":"2023-02-27","kind":"tax_withholding","acquired":false,"shares":2975,"price":10.36,"value":30821.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Dynavax Technologies Corporation of 2,975 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of common stock to the reporting person on February 27, 2023."}],"balance_after":2359,"source":{"system":"sec-edgar","filing":"0001209191-23-014170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123014170/doc4.xml","form_type":"4"}},{"id":1984495,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2023-03-01T16:52:25.000Z","date":"2023-02-27","kind":"exercise","acquired":true,"shares":5334,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":5334,"source":{"system":"sec-edgar","filing":"0001209191-23-014170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123014170/doc4.xml","form_type":"4"}},{"id":2004376,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-21T17:25:09.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares\nsubject to the option vesting each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares\nsubject to the option vesting each month thereafter."}],"balance_after":100000,"derivative":{"exercise_price":11.12,"expiration_date":"2030-02-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-011297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123011297/doc4.xml","form_type":"4"}},{"id":2398924,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Restricted Stock Unit","published_at":"2022-02-14T21:09:35.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022"}],"balance_after":16000,"derivative":{"underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-22-009592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122009592/doc4.xml","form_type":"4"}},{"id":2398923,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-14T21:09:35.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":90500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 10, 2022, and one thirty-sixth (1/36) of the shares\nsubject to the option vesting each month thereafter."}],"balance_after":90500,"derivative":{"exercise_price":12.74,"expiration_date":"2029-02-09","underlying":"Common Stock","underlying_shares":90500},"source":{"system":"sec-edgar","filing":"0001209191-22-009592","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122009592/doc4.xml","form_type":"4"}},{"id":2821749,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-02T19:58:17.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of March 1, 2021, and one thirty-sixth (1/36) of the shares\nsubject to the option vesting each month thereafter."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of March 1, 2021, and one thirty-sixth (1/36) of the shares\nsubject to the option vesting each month thereafter."}],"balance_after":350000,"derivative":{"exercise_price":8.9,"expiration_date":"2028-02-29","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-21-016520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919121016520/doc4.xml","form_type":"4"}},{"id":2953326,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-08T21:01:36.000Z","date":"2020-12-04","kind":"exercise","acquired":false,"shares":5639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, granted as an annual performance award, is presently exercisable in full."}],"balance_after":0,"derivative":{"exercise_price":9.12,"expiration_date":"2026-03-01","underlying":"Class A Common Stock","underlying_shares":5639},"source":{"system":"sec-edgar","filing":"0001209191-20-062229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120062229/doc4.xml","form_type":"4"}},{"id":2953325,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-12-08T21:01:36.000Z","date":"2020-12-04","kind":"sale","acquired":false,"shares":5639,"price":12.5,"value":70487.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":93041,"source":{"system":"sec-edgar","filing":"0001209191-20-062229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120062229/doc4.xml","form_type":"4"}},{"id":2953324,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-12-08T21:01:36.000Z","date":"2020-12-04","kind":"exercise","acquired":true,"shares":5639,"price":9.12,"value":51427.68,"ownership":{"direct":true},"balance_after":98680,"source":{"system":"sec-edgar","filing":"0001209191-20-062229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120062229/doc4.xml","form_type":"4"}},{"id":2981065,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-11-13T21:02:17.000Z","date":"2020-11-11","kind":"exercise","acquired":false,"shares":3561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, granted as a promotion award, is presently exercisable in full."}],"balance_after":0,"derivative":{"exercise_price":9.31,"expiration_date":"2025-10-01","underlying":"Class A Common Stock","underlying_shares":3561},"source":{"system":"sec-edgar","filing":"0001209191-20-058270","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120058270/doc4.xml","form_type":"4"}},{"id":2981064,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-11-13T21:02:17.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":3561,"price":11.75,"value":41841.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":93041,"source":{"system":"sec-edgar","filing":"0001209191-20-058270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120058270/doc4.xml","form_type":"4"}},{"id":2981063,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-11-13T21:02:17.000Z","date":"2020-11-11","kind":"exercise","acquired":true,"shares":3561,"price":9.31,"value":33152.91,"ownership":{"direct":true},"balance_after":96602,"source":{"system":"sec-edgar","filing":"0001209191-20-058270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120058270/doc4.xml","form_type":"4"}},{"id":2986411,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-11-10T21:10:33.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":100,"price":10.92,"value":1092.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 15, 2017."}],"balance_after":93041,"source":{"system":"sec-edgar","filing":"0001209191-20-057611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120057611/doc4.xml","form_type":"4"}},{"id":2986410,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-11-10T21:10:33.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":825,"price":10.92,"value":9009.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding\nobligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16,\n2016."}],"balance_after":93141,"source":{"system":"sec-edgar","filing":"0001209191-20-057611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120057611/doc4.xml","form_type":"4"}},{"id":2986409,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-11-10T21:10:33.000Z","date":"2020-11-06","kind":"sale","acquired":false,"shares":1872,"price":11.25,"value":21060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":93966,"source":{"system":"sec-edgar","filing":"0001209191-20-057611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120057611/doc4.xml","form_type":"4"}},{"id":3008125,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-10-13T20:03:58.000Z","date":"2020-10-08","kind":"sale","acquired":false,"shares":22714,"price":10.5,"value":238497.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":95838,"source":{"system":"sec-edgar","filing":"0001209191-20-054621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120054621/doc4.xml","form_type":"4"}},{"id":3052237,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-08-19T20:01:44.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":575,"price":10.14,"value":5830.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on July 9, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person acquired 980 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2020."}],"balance_after":118552,"source":{"system":"sec-edgar","filing":"0001209191-20-047469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120047469/doc4.xml","form_type":"4"}},{"id":3150759,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-05-13T21:20:50.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":595,"price":10.35,"value":6158.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding\nobligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 29,\n2019."}],"balance_after":118147,"source":{"system":"sec-edgar","filing":"0001209191-20-028899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120028899/doc4.xml","form_type":"4"}},{"id":3150758,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-05-13T21:20:50.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":558,"price":10.35,"value":5775.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding\nobligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1,\n2019."}],"balance_after":118742,"source":{"system":"sec-edgar","filing":"0001209191-20-028899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120028899/doc4.xml","form_type":"4"}},{"id":3238004,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-03-02T21:28:44.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":36173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":119300,"source":{"system":"sec-edgar","filing":"0001209191-20-014464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120014464/doc4.xml","form_type":"4"}},{"id":3249156,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":1695,"price":11.63,"value":19712.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":83127,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3249155,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":303,"price":11.63,"value":3523.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":84822,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3249154,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":793,"price":11.63,"value":9222.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":85125,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3249153,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":303,"price":11.63,"value":3523.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":85918,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3249152,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":504,"price":11.63,"value":5861.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":86221,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3249151,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:36:40.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":302,"price":11.63,"value":3512.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person acquired 460 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2019."}],"balance_after":86725,"source":{"system":"sec-edgar","filing":"0001209191-20-012484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012484/doc4.xml","form_type":"4"}},{"id":3336765,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2019-12-18T21:36:37.000Z","date":"2019-12-16","kind":"grant","acquired":true,"shares":8230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units, granted as a special retention award, vest as to 100% of the shares of Class A Common Stock on November 18, 2021."}],"balance_after":86567,"source":{"system":"sec-edgar","filing":"0001209191-19-061134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119061134/doc4.xml","form_type":"4"}},{"id":3374406,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2019-11-12T23:26:22.000Z","date":"2019-11-08","kind":"sale","acquired":false,"shares":107,"price":11,"value":1177.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 15, 2017."}],"balance_after":78337,"source":{"system":"sec-edgar","filing":"0001209191-19-056191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119056191/doc4.xml","form_type":"4"}},{"id":3374405,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2019-11-12T23:26:22.000Z","date":"2019-11-08","kind":"sale","acquired":false,"shares":880,"price":11,"value":9680.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16, 2016."}],"balance_after":78444,"source":{"system":"sec-edgar","filing":"0001209191-19-056191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119056191/doc4.xml","form_type":"4"}},{"id":3463517,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":67090,"kind":"person","name":"MacDonald Kelly","position":1,"cik":"0001781117","reported_name":"MacDonald Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Class A Common Stock","published_at":"2019-07-11T20:06:34.000Z","date":"2019-07-09","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units, granted as a promotion award, vest as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":79324,"source":{"system":"sec-edgar","filing":"0001209191-19-041827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119041827/doc4.xml","form_type":"4"}}]}